Table 4.
Recent reports on stereotactic body radiation therapy for lung or liver metastases
| Aurhor (reference) | Lesion /Patients, n | CRC rate, % | Median f/u period, m | Median MTD, mm | Median GTV, mL | LC, % | PFS, % | OS, % | AE ≥ G3, % | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 yr | 2 yr | 1 yr | 2 yr | 1 yr | 2 yr | |||||||
| Rusthoven (7) | 63/ 38 | 24 | 15 | NA | 4.2 | 100 | 96 | NA | NA | NA | 39 | 8 |
| Rurthoven (8) | 63/ 47 | 32 | 16 | 27 | 14.9 | 95 | 92 | NA | NA | NA | 30 | 2 |
| Binkley (10) | 122/ 77 | 21 | 22 | NA | 3.7 | 91 | 84 | NA | 25 | 94 | 75 | 0 |
| Andratschke (13) | 91/ 52 | 42 | 17 | 28 | NA | NA | 82 | 35 | 18 | 70 | 45 | 1.9(≥G2) |
| Ricard (14) | 77/ 61 | 21 | 20 | NA | NA | NA | 89 | NA | 32 | NA | 67 | 2 |
| Filippi (15) | 59/ 40 | 100 | 46 | 15 | NA | 93 | NA | 49 | 27 | 84 | 73 | 7.5(≥G2) |
| Agolli (16) | 69/ 44 | 100 | 36 | 14 | NA | NA | NA | NA | 20 | NA | 68 | 0 |
| Katz (17) | 74/ 69 | 29 | 15 | 27 | NA | 76 | 57 | 24 | NA | 78 | 37 | 0 |
| Scorsetti (18) | 52/ 42 | 100 | 24 | 35 | NA | 95 | 91 | NA | 46 | NA | 65 | 0 |
| Joo (19) | 103/ 70 | 100 | 34 | 29 | NA | 93 | 89 | NA | 35 | NA | 75 | NA |
| Wang (25) | 134/ 95 | 18 | 17 | NA | 14.6 | 98 | 91 | 51 | 29 | 83 | 61 | 3 |
| Vautrauers-Dewas (26) | 62/ 42 | 67 | 14 | 25 | 13 | 90 | 86 | NA | NA | 94 | 48 | 6.3 |
| Present study | 114/ 76 | 61 | 21 | 19 | 3.2 | 89 | 78 | 38 | 20 | 96 | 76 | 1.3 |
CRC colorectal cancer, MTD maximum tumor diameter, GTV gross tumor volume, LC local control, PFS progression free survival, OS overall survival, AE adverse event, NA: